References

  1. WHO consolidated guidelines on tuberculosis Module 1:  Prevention  –  tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331170).
  2. Houben R, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modeling. PLoS Med. 2016;13(10):e1002152 (https://pubmed.ncbi.nlm.nih. gov/27780211/).
  3. Long R, Divangani M, Schwartzman K. Chapter 2: Transmission and pathogenesis of tuberculosis. In: Menzies D (ed), Canadian Tuberculosis Standards (8th edition). Ottawa: Canadian Thoracic Society; 2022:22–32 (https://doi.org/10.1080/24745332.2022.2035540).
  4. Martinez L, Cords O, Horsburgh CR, Andrews JR. Risk of tuberculosis in children after close exposure: an individual-participant meta-analysis including 137,647 children from 46 cohort studies. Lancet. 2020;395(10228):973–84 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289654/).
  5. Gupta RK, Calderwood CJ, Yavlinsky A, Krutikov M, Quartagno M, Aichelburg MC et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine. 2020;26(12):1941–9 (https://www.nature.com/articles/s41591-020-1076-0).
  6. Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549 (https://www.ncbi.nlm.nih.gov/pubmed/32156698 https:// www.bmj.com/content/bmj/368/bmj.m549.full.pdf).
  7. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection (WHO- UCN-TB-2022.1). Geneva: World Health Organization; 2022 (https://apps.who.int/iris/ handle/10665/352802).
  8. Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/ handle/10665/351191).
  9. Mantoux MC. La voie intradermique en tuberculinothérapie. Presse Med. 1912;20:146 8.
  10. Stewart CJ. Skin sensitivity to human, avian and BCG PPDs after BCG vaccination. Tubercle. 1968;49(1):84–91   (http://www.ncbi.nlm.nih.gov/pubmed/5690764).
  11. Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis. 1992;145(3):621 5 (https://pubmed.ncbi.nlm.nih.gov/1546843/).
  12. Palmer C, Edwards L. Identifying the tuberculous infected. The dual-test technique. JAMA. 1968;205(3):167–9    (http://www.ncbi.nlm.nih.gov/pubmed/5694785).
  13. Anderson P, Munk M, Pollock S, Doherty T. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099–104 (http://www.ncbi.nlm.nih.gov/pubmed/11009160).
  14. WHO consolidated guidelines on tuberculosis Module 3: Diagnosis – tests for tuberculosis infection. Geneva: World Health Organization; 2022. (https://apps.who.int/iris/rest/bitstreams/1467620/retrieve).
  15. Alsdurf H, Hill P, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269 (https://pubmed.ncbi.nlm.nih.gov/27522233/).
  16. Comstock G, Edwards L, Livesay V. Tuberculosis morbidity in the US Navy: its distribution and decline. Am Rev Respir Dis. 1974;110(5):572–80 (https://pubmed.ncbi.nlm.nih.gov/4429253/).
  17. Horwitz O, Wilbek E, Erickson P. Epidemiological basis of tuberculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ. 1969;41:95–113 (https://pubmed.ncbi.nlm.nih.gov/5309087/).
  18. Pai M, Kuimoto D, Jamieson F, Menzies D. Diagnosis of latent tuberculosis infection. In: Menzies D (ed), 7th ed, Canadian TB standards. Ottawa: Public Health Agency and Canadian Thoracic Society; 2013 (https://www.canada.ca/en/public-health/services/infectious-diseases/canadian-tuberculosis- standards-7th-edition.html).
  19. Marais B, Gie R, Schaaf H, Hesseling A, Obihara C, Starke J et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2006;8(4):392–402 (https://pubmed.ncbi.nlm.nih.gov/15141729/).
  20. Bastos ML, Melnychuk L, Campbell JR, Oxlade O, Menzies D. The latent tuberculosis cascade- of-care among people living with HIV: A systematic review and meta-analysis. PLoS Med. 2021;18(9):e1003703 (https://www.ncbi.nlm.nih.gov/pubmed/34492003).
  21. Comstock G. False tuberculin test results. Chest. 1975;68(3):465–9 (https://pubmed.ncbi.nlm.nih.gov/1157566/).
  22. Reichman L, O’Day R. The influence of a history of a previous test on the prevalence and size of reactions to tuberculin. Am Rev Respir Dis. 1977;115:737–41 (https://pubmed.ncbi.nlm.nih. gov/404946/).
  23. Edwards P. Tuberculin negative? New Eng J Med. 1972;286(7):373–4 (https://pubmed.ncbi.nlm. nih.gov/5008560/).
  24. Chorba T. COVID mRNA vaccines, TST, and IGRA – follow-up: 31 August 2021 [website]. Atlanta: United States Centers for Disease Control and Prevention; 2021 (https://www.cdc.gov/tb/ publications/letters/2021/covid-mrna-followUp.html).
  25. WHO information note. COVID-19: considerations for tuberculosis (TB). Geneva: World Health Organization; 2021 (https://apps.who.int/iris/rest/bitstreams/1344785/retrieve).
  26. Tarlo S, Day J, Mann P, Day M. Immediate hypersensitivity to tuberculin in-vivo and in-vitro studies. Chest. 1977;71(1):33–7 (https://pubmed.ncbi.nlm.nih.gov/11970/).
  27. Spiteri M, Bowman A, Assefi A, Clarke S. Life threatening reaction to tuberculin testing. BMJ. 1986;293:243–4 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1341180/).
  28. WHO operational handbook on tuberculosis Module 2: Screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 (http://apps.who.int/iris/handle/10665/340256).
  29. WHO consolidated guidelines on tuberculosis Module 3: Diagnosis – rapid diagnostics for tuberculosis detection. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/332862).
  30. WHO operational handbook on tuberculosis  Module  1:  Prevention  –  tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331525). 
  31. WHO operational handbook on tuberculosis Module 3: Diagnosis – rapid diagnostics for tuberculosis detection 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342369).
  32. Seibert F, Glenn J. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. Am Rev Tuberc. 1941;44:9 (https://www.atsjournals.org/doi/abs/10.1164/ art.1941.44.1.9).
  33. Snider D, Farer L. Package inserts for antituberculosis drugs and tuberculins. Am Rev Respir Dis. 1985;131:809–10 (https://www.atsjournals.org/doi/abs/10.1164/arrd.1985.131.6.809).
  34. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull World Health Organ. 1955;12(1–2):63–83 (http://www.ncbi.nlm.nih.gov/pubmed/14351968).
  35. Farhat M, Greenaway C, Pai M, Menzies D. False positive tuberculin skin tests – what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1–13 (https://www.ingentaconnect.com/content/iuatld/ijtld/2006/00000010/00000011/art00003).
  36. Lewinsohn D, Leonard M, Lobue P. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5 (https://pubmed.ncbi.nlm.nih.gov/28052967/).
  37. Cy-Tb package insert. Pune: Serum Institute of India; 2022.
  38. Hamada Y, Kontsevaya I, Surkova E, Wang T, Liu V, Ziganshina L et al. A systematic review on the safety of novel Mycobacterium tuberculosis specific antigen-based skin tests for TB infection compared to tuberculin skin tests or blood-based in vitro interferon-gamma release assays. In press.
  39. Comstock G, Edwards L, Philip R, Winn W. A comparison in the United States of America of two tuberculins, PPD-S and PPD-RT 23. Bull World Health Organ. 1964;31:161–70 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2555164/).
  40. Diaskintest package insert. Russian Federation: Generium; 2022.
  41. C-TST package insert. China: Anhui Zhifei Longcom; 2022.
  42. Menzies D, Doherty T. Diagnosis of latent tuberculosis infection. In: Raviglione M (ed), Reichman and Hershfield’s tuberculosis, a comprehensive international approach. New York: Informa Healthcare USA; 2006:215–63 (https://www.taylorfrancis.com/chapters/edit/10.3109/9780203908464-15/diagnosis-latent-tuberculosis-infection-dick-menzies-mark-doherty).
  43. Injection – TST technique training (English) [website]. Montreal: McGill International TB Centre; 2021 (https://www.youtube.com/watch?v=tRqumpCb_Js&list=PLwoB2EX6lRZRWCw4yyYHDQAA DC9QO892V&index=5).
  44. Cadernos de saude publica (Reports in public health) [website]. Rio de Janeiro: Escola Nacional de Saude Publica Sergio Arouca; 2022 (http://cadernos.ensp.fiocruz.br/csp/?404).
  45. Moayedi-Nia S, Barss L, Oxlade O, Valiquette C, Ly MX, Campbell JR et al. The mTST – an mHealth approach for training and quality assurance of tuberculin skin test administration and reading. PLoS One. 2019;14(4):e0215240 (https://www.ncbi.nlm.nih.gov/pubmed/30995275).
  46. Guide for reviewers performing the TST quality assurance – quantitative assessment of TST injection [website]. Montreal: McGill International TB Centre; 2019 (https://www.youtube.com/ watch?v=PsBTYiEAKcc&t=4s).
  47. Instructions for healthcare workers: how to take mTST photos [website]. Montreal: McGill International TB Centre; 2019 (https://www.youtube.com/watch?v=7Lbt84YCsiM).
  48. The WHO standard tuberculin test. Geneva: World Health Organization; 1963 (https://apps.who.int/iris/handle/10665/112241).
  49. Duboczy B, Brown B. Multiple readings and determination of maximal intensity of tuberculin reaction. Am Rev Respir Dis. 1960;82:60–7 (https://pubmed.ncbi.nlm.nih.gov/13724589/).
  50. Sokal J. Measurement of delayed skin-test responses. New Eng J Med. 1975;293:501–2 (https://www.nejm.org/doi/full/10.1056/NEJM197509042931013).
  51. Hanson M, Comstock G. Efficacy of hydrocortisone ointment in the treatment of local reactions to tuberculin skin tests. Am Rev Respir Dis. 1968;97:472–3 (https://www.atsjournals.org/doi/abs/10.1164/arrd.1968.97.3.472).
  52. QuantiFERON®-TB Gold Plus (QFT®-Plus) ELISA package insert. Germany: QIAGEN; 2019 (http://www.quantiferon.com/wp-content/uploads/2017/04/English_QFTPlus_ELISA_R04_022016.pdf).
  53. WANTAI TB-IGRA package insert. Beijing: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd;2022.
  54. T-SPOT.TB package insert. United Kingdom: Oxford Immunotec; 2017 (http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf).
  55. Oh C, Ortiz-Brizuela E, Bastos M, Menzies D. Comparing the diagnostic performance of QuantiFERON-TB Gold Plus to other tests of latent tuberculosis infection: a systematic review and meta-analysis. Clin Infect Dis. 2020;73(5):e1116–e25 (https://pubmed.ncbi.nlm.nih.gov/33289038/).
  56. Tuberculosis (TB) Prevention and Control Program. Tuberculin skin testing (TST): storage of tuberculin and need for orders to administer. Minnesota: Minnesota Department of Health; 2013 (https://www.health.state.mn.us/diseases/tb/tstfsprov.pdf).
  57. Gloria L, Bastos M, Santos Junior B, Trajman A. A simple protocol for tuberculin skin test reading certification. Cad Saude Publica. 2021;37(8):e00027321 (https://www.ncbi.nlm.nih.gov/pubmed/34495087).
  58. Oxlade O, Benedetti A, Adjobimey M, Alsdurf H, Anagonou S, Cook VJ et al. Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health. 2021;6(5):e272–e82 (https://www.ncbi.nlm.nih.gov/pubmed/33765453).
  59. Bastos ML, Oxlade O, Benedetti A, Fregonese F, Valiquette C, Lira SCC et al. A public health approach to increase treatment of latent TB among household contacts in Brazil. Int J Tuberc Lung Dis. 2020;24(10):1000–8 (https://www.ncbi.nlm.nih.gov/pubmed/33126931).
  60. Barss L, Moayedi-Nia S, Campbell JR, Oxlade O, Menzies D. Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24(1):100–9 (https://pubmed.ncbi.nlm.nih.gov/32005312/).
  61. ACT4 registry analysis tools [website]. Quebec: McGill University; 2022 (https://www.mcgill.ca/tb/act4-registry-analysis-tools).
  62. GLI specimen referral toolkit [website]. Geneva: Stop TB Partnership; 2019 (https://www.stoptb.org/gli-guidance-and-tools/gli-specimen-referral-toolkit).
  63. Alsdurf H, Oxlade O, Adjobimey M, Ahmad Khan F, Bastos M, Bedingfield N et al. Resource implications of the latent tuberculosis cascade of care: a time and motion study in five countries. BMC Health Serv Res. 2020;20(1):341 (https://www.ncbi.nlm.nih.gov/pubmed/32316963).
  64. Training slides for tuberculin skin testing (TST) [website]. Montreal: McGill International TB Centre; 2022 (https://www.mcgill.ca/tb/files/tb/tuberculin_skin_testing_tst_technique_training_ feb202018_english.pdf). 
  65. Reading – TST technique training (English) [website]. Montreal: McGill International TB Centre; 2021 (https://www.youtube.com/watch?v=xsV7oHBdMEs&list=PLwoB2EX6lRZRWCw4yyYHDQA ADC9QO892V&index=4).
  66. Tebruegge M, Buonsenso D, Brinkmann F, Noguera-Julian A, Pavic I, Arbore AS et al. European shortage of purified protein derivative and its impact on tuberculosis screening practices. Int J Tuberc Lung Dis. 2016;20(10):1293–9 (https://www.ncbi.nlm.nih.gov/pubmed/27725037).
  67. Preventing TB [website]. Geneva: World Health Organization; 2022 (https://www.who.int/activities/preventing-tb).
  68. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/79199).

Book navigation